<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>1255 cases of <z:hpo ids='HP_0001909'>leukemia</z:hpo>-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> were tested between 1972 and 1984 by multiple marker analysis </plain></SENT>
<SENT sid="1" pm="."><plain>Routine <z:hpo ids='HP_0001909'>leukemia</z:hpo> phenotyping was performed using standard morphological and cytochemical techniques in combination with clinical and histo-pathological information; the main emphasis was put on immunological surface marker analysis using erythrocyte rosette assays, TdT and a large panel of poly- and monoclonal antibody tests </plain></SENT>
<SENT sid="2" pm="."><plain>The 1255 cases were divided into these major types and subtypes: 349 cases of ALL and related immature T- and Burkitt-<z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">cALL</z:e>, <z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">pre B-ALL</z:e>, <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> and Burkitt-<z:hpo ids='HP_0002665'>lymphomas</z:hpo>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and immature, mostly leukemic T-<z:hpo ids='HP_0002665'>lymphomas</z:hpo>, Null-ALL), 454 cases of mature T- and B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (T-CLL, <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e>, <z:e sem="disease" ids="C0036920" disease_type="Neoplastic Process" abbrv="">Sezary-syndrome</z:e>, T-<z:hpo ids='HP_0002665'>lymphomas</z:hpo>, B-CLL, hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, B-<z:hpo ids='HP_0002665'>lymphomas</z:hpo>), 263 cases of <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, AMMoL/AMoL), 182 cases of <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemias</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, CMoL, <z:mp ids='MP_0005481'>CML</z:mp> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>), 6 cases of <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> and 1 case of megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>A simplified classification scheme which has been used in our laboratories is presented </plain></SENT>
<SENT sid="4" pm="."><plain>Phenotyping is of diagnostic, prognostic and therapeutic relevance, most evidently for patients with ALL </plain></SENT>
<SENT sid="5" pm="."><plain>Routine <z:hpo ids='HP_0001909'>leukemia</z:hpo> phenotyping should be performed with highly standardized techniques and reagents and by combining information from several fields in the multiple marker analysis </plain></SENT>
<SENT sid="6" pm="."><plain>New areas of <z:hpo ids='HP_0001909'>leukemia</z:hpo> research might become very useful for the routine procedure of phenotyping </plain></SENT>
</text></document>